Celltrion, Inc.: Business Overview, Financials & Competitive Analysis
Celltrion, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Celltrion is a high-growth South Korean biopharmaceutical leader positioned to capture significant value through biosimilar market dominance and emerging innovative therapeutic pipelines. In 2024, Celltrion's revenue was 3.56 trillion, an increase of 63.45% compared to the previous year's 2.18 trillion. The company demonstrates strong fundamentals with rapid growth and strategic.
What is Celltrion, Inc.'s industry? Celltrion, Inc. (celltrion.com) operates in Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics. AskCyborg classifies Celltrion, Inc. under Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics in its company registry.
Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. The company offers biosimilars including Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for non-hodgkin's lymph...
Cyborg Score thesis
Celltrion is a high-growth South Korean biopharmaceutical leader positioned to capture significant value through biosimilar...
Read the full analyst-debate transcript →Get the Latest Celltrion, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeCelltrion, Inc. Overview
Pro stress-test →Celltrion is a biopharmaceutical company headquartered in Incheon, South Korea. The company offers biosimilars including Remsima for rheumatoid arthritis and inflammatory bowel disease, Truxima for non-hodgkin's lymphoma, Herzuma for metastatic breast and gastric cancer, and multiple other therapeutic products. Celltrion provides one-stop solutions for the entire process of biopharmaceutical business from R&D to clinical trials, regulatory affairs, production and distribution.
Strategic Profile
Pro stress-test →Celltrion is transitioning from biosimilar excellence to next-generation innovative therapeutics with plans to expand manufacturing and R&D capabilities in the U.S. to support long-term growth and enhance supply resilience. Following a record year in 2025, Celltrion has entered a full-scale growth phase, targeting consolidated revenue of KRW 5.3 trillion in 2026.
Competitive Landscape
Pro stress-test →Key competitors include Samsung Biologics, ALTEOGEN, Voronoi, and SK bioscience within South Korea's biosimilar sector. Celltrion competes globally with international biosimilar manufacturers while establishing differentiation through manufacturing scale and innovative pipeline development focused on ADCs and multi-specific antibodies.
Industry Context
Celltrion, Inc. operates in Biopharmaceutical/Biotechnology - Biosimilars & Innovative Therapeutics.
Key facts
Founded: 2002 · Headquarters: Incheon, South Korea · Employees: 2680 · Revenue: $2.6B (2024) · Market cap: $37.8B